Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Next Previous
Trial Profile

A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TELESTAR
  • Sponsors Lexicon Pharmaceuticals

    • Most Recent Events

    • 28 Sep 2021 Results of pooled analysis of two phase III clinical TELESTAR and TELECAST trials assessing weight changes and nutritional metabolic disorder status, including cholesterol and albumin concentrations published in the Clinical Therapeutics
    • 11 Mar 2020 A model was developed to evaluate the 5-year budget impact of introducing telotristat ethyl to standard care in Swedish patients with uncontrolled carcinoid syndrome ;results published in the PharmacoEconomics
    • 19 Jan 2019 Results assessing the patient-reported outcomes, presented at the 2019 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top